Epidemiology
Endocrine tumours of the gastrointestinal tract make up about 2% of all malignancies of the digestive system. Although the incidence of endocrine tumours of the gastrointestinal tract is generally considered to be 1/ 100,000/yr for carcinoid tumours and 0.4/100,000/yr for pancreatic tumours [1] . The majority of information dealing with the epidemiology of endocrine tumours of the gastrointestinal tract derives from a handful of studies on clinical and pathological registers.
One such study on the British Cancer Register comprising over four thousand cases with malignant or uncertain behaviour from the period 1979 to 1989 reported incidence rates of around 1/100,000, with an excess of females, particularly within an early reproductive age group (15-22 years) [2] . Another comprehensive report (Modlin and Sandor, 1997) involving 8305 cases of malignant carcinoid tumours, registered by the National Cancer Institute, also revealed higher incidence rates of carcinoid tumours in females than in males [3] . The overall five-year survival rate was found to be over 50%. A remarkable proportion of the cases were associated with other malignancies, the most frequent sites being the gastrointestinal tract followed by the lungs. This study also revealed that the incidence of the disease in the USA had increased over the past two decades. The most recent information on the epidemiology of carcinoid tumours derives from a study of the Vaud Cancer Registry in Switzerland of endocrine tumours in the gastrointestinal tract and elsewhere. This study regarded 215 well-differentiated endocrine tumours, as well as 218 poorly-differentiated endocrine carcinomas registered from 1974 to 1997 in the resident population of the Canton. The results confirmed the concept that the incidence of both categories increases with age, and that the risk is apparently higher in males than in females [4] .
Future studies should be able to take advantage of the impact in recent years of improvements in immunohistochemical techniques on the histopathological diagnosis and on the more streamlined new WHO histopathological classification.
Carcinoids and the carcinoid syndrome
Carcinoids account for 55% of all endocrine tumours. They derive from gastrointestinal enterochromaffin (EC) and EC-like (ECL) cells and from extra-intestinal endocrine cells (of the lung, ovary, etc.). The majority are classified on the basis of embryological origin as tumours of the foregut tumors (bronchi, stomach, pancreas, gall bladder, jejunum, duodenum), midgut (ileum, appendix, right colon) and hindgut (left colon, rectum); other rarer sites are the thymus, esophagus, bile ducts, Meckel's diverticulum and breast [5] .
The appendix is by far the most common site, accounting for about half of all carcinoids. Carcinoids of the appendix are most often small, solitary and noninvasive. For the most part, they are discovered by chance upon histological examination during surgery for appendectomy. Carcinoids of the ileum have a more malignant course. Local invasion is usually present by the time of diagnosis, and lymph node or liver metastasis is frequent. On the other hand, carcinoids of the colon and the rectum, which are most often casual findings during endoscopic investigations, generally have a benign course.
The carcinoid syndrome occurs in less then 10% of patients with carcinoid tumours and, with a few exceptions, only manifests itself in the presence of liver metastasis. Nevertheless, some patients who have extensive liver metastases do not present the syndrome. The carcinoid syndrome is subdivided into typical and atypical varieties: the typical syndrome is present in 95% of the cases and the most common symptoms are flushing, diarrhoea, cardiac fibrosis, wheezing, dyspnoea and pellagra. The atypical syndrome, which is much less common (5%), consists of a prolonged flush, headache, lacrimation, and bronchoconstriction [6] . In turn, these two types of syndrome are triggered by humoral mediators: for the typical syndrome, serotonin, kallikrein, tachykinins and prostaglandins; for the atypical syndrome, 5-hydroxytryptophan, histamine and other bioactive peptides [7] . The most immediate life-threatening complication of the syndrome is the carcinoid crisis, which is mostly observed in patients with foregut and midgut carcinoid tumours. Although the carcinoid crisis usually occurs spontaneously, it may also be associated with stress, anaesthesia or hepatic embolization.
The principal features of the carcinoid syndrome are diarrhoea and flushing. The flushing presents quite differently in the two varieties of the syndrome. In the atypical one, it is purplish or violaceous and lasts for many hours, after which time it is followed by teleangectasia, localized in the trunk and limbs; it can result in skin hypertrophy with the 'classic leonine face'. This type of flush occurs in the absence of triggering foods. On the other hand, the typical syndrome is associated with brief pink or red flushing localised in the face and in the nipple-line, triggered by alcohol or tyramine-containing foods, chocolate, walnuts and bananas.
The diarrhoea associated with the carcinoid syndrome is usually due to secretory mechanisms and gastrointestinal motor abnormalities, particularly of the small intestine and right colon, gut lymphangectasia and/or bacterial overgrowth. In the early phases of the disease, the major mechanisms are secretory and gastrointestinal dysmotility factors, whereas the later phases are also associated with gut lymphangectasia and bacterial overgrowth [8] .
Many patients with carcinoid syndrome develop cardiac manifestations due to endocardial fibrosis which can cause valvular heart disease. Usually affecting the proximal side of the tricuspid and pulmonary valves and leading to tricuspid insufficiency, pulmonary stenosis and secondary right-side heart failure. The patients with the right heart disease have significantly higher plasma levels of tachykinins and excretion of 5-hydroxyindolacetic acid (5-HIAA). Left-sided valvular diseases may occur in association with bronchial carcinoids, presumably because venous effluent from these tumours passes directly into the pulmonary veins, avoiding inactivation of the hormone mediators in the lung [9] .
A small percentage (7%) of patients with metastatic carcinoid tumours may present symptoms of protein malnutrition or mild pellagra, since these tumours synthesise large amount of serotonin from circulatory tryptophan. Up to 50% of the dietary tryptophan may be converted to serotonin, which can sometimes leave inadequate substrate for incorporation into proteins and conversion to niacin [6] .
Endocrine tumours of the pancreas

Insulinomas
Insulinomas are the most common of the functioning tumours of the pancreas. They mainly occur in males between 30 and 60 years of age. In about 70% of cases, the insulinoma presents as a solitary nodule and runs a benign course. In about 10% of cases, the tumour is made up of multiple nodules. In 8% to 10% of cases, the tumour is malignant and can lead to widespread metastasis. Furthermore, a small percentage of cases are associated with MEN1 tumours.
Insulinomas are almost always located in the pancreas, even though aberrant cases have been described in the duodenum, ileum, lung and cervix. The tumour is characterised by hypersecretion of insulin, which is responsible for the associated syndrome consisting of neuroglycopaenic symptoms such as paresthesias, blurred vision, mental confusion and neuropsychiatric manifestations including coma, along with symptoms of adrenergic hyperactivation such as perspiration, hunger, tremors and tachycardia. When diagnosis is made late, hypoglycaemia may even provoke permanent cerebral damage. The symptomatology can be partially masked by a tendency to hyperalimentation in order to compensate for the hypoglycaemia. For this reason, insulinoma patients are often overweight [10] .
Gastrinomas
Gastrinomas are the second most frequent tumour of the pancreas. In 80% of cases, the tumour is located in the gastrinoma triangle, which includes the duodenum and the pancreas. Less frequent sites are the small intestine and the stomach. Duodenal localisations are characteristically associated with the MEN1 syndrome. These tumours are usually small in size and often multifocal, and are therefore difficult to detect either by traditional imaging methods or at surgery.
About 60% of all gastrinomas run a malignant course. They manifest with the characteristic ZollingerEllison syndrome, which is caused by hypergastrinemia associated with hypersecretion of gastric acid. This situation generally leads to the onset of a peptic ulcer, which can be single or multiple. The most common sites are the stomach and duodenum. Less frequent ones are the oesophagus, distal duodenum or the jejunum. The other characteristic component of the syndrome is diarrhoea of the secretory or motor variety, which can precede, accompany or follow the ulcerous disease, or in some cases may even be the only manifestation of the syndrome. The diarrhoea is always associated with hypergastrinaemia and hypersecretion of gastric acid. This makes it easily distinguishable from the diarrhoea found in the Verner-Morrison syndrome, which is associated with gastric hypochlorhydria [11] . In patients who present Zollinger-Ellison syndrome, especially when associated with MEN1, the trophic effects of prolonged hypergastrinemia on ECL cells lead to the formation of gastric carcinoids, which may involve the body and fundus of the stomach. Lymph node and liver metastasis is present in 75%-80% of patients at the time of diagnosis. Bone metastasis, which appears in about 12% of all gastrinoma patients, is associated with short survival.
The complications of the ulcerous disease are perforation, haemorrhage and pyloric stenosis. For a long time, these accounted for the main causes of death among gastrinoma patients. Nowadays, the pharmacological use of proton pump inhibitors has attenuated the presentation of the Zollinger-Ellison syndrome by strongly inhibiting gastric acid secretion. Indeed, proton pump inhibitors are capable of healing not only common peptic ulcers but also those related to gastrinoma [12] .
Vipomas
VIP-secreting tumours, otherwise known as vipomas, generally have a sporadic presentation. They are much more common in females (with a male/female ratio of 1/3), and most frequently occur around the fourth decade of life. In 90% of cases are of pancreatic origin, while the remaining 10% are of nervous origin [13] . Indeed, ganglioneuroma and neuroblastoma patients frequently present the Verner-Morrison syndrome, which results from hypersecretion of VIP. The syndrome includes characteristic watery choleriform diarrhoea, which is intermittent in 53% and continuous in 47% of cases. Chronic diarrhoea provokes severe dehydration, compromising the hydroelectrolytic equilibrium, with consequent marked asthaenia, cramps in the limbs leading to tetany and cardiac alterations. If not corrected, the associated hypopotassaemia can become severe enough to provoke sudden death. Less frequent symptoms are diabetic-like sugar intolerance (50%) and episodes of cutaneous flushing in 20%-60% of cases [14] .
Glucagonomas
Glucagonomas account for about 4% of all GEP endocrine tumors. They are somewhat more common in females (55%) and are more frequently observed after 45 years of age. Glucagonomas are almost exclusively found in the pancreas. They generally have a highly malignant behaviour. Metatasis occurs in the liver in 90% of cases, in the lymph nodes in 30%. Less frequent sites are the vertebrae, ovaries or peritoneum. Glucagonoma is rarely associated with MEN1. The clinical syndrome is characterised by skin rash, diabetes mellitus, weight loss and hypoaminoacidemia. Necrolytic migratory erythema is the most frequent cutaneous manifestation, being present in about 90% of patients, either on the abdomen, perineum, face or distal extremities. The initially erythematous lesions subsequently become papular, and their healing leads to hyperpigmentation of the area involved. Diabetes mellitus, which is present in 87% of cases, can precede the appearance of the rash by many years. Weight loss due to the hypercatabolic action of the glucagon is observed in almost all glucagonoma patients, and may be as much as 20-30 kg. Less common symptoms are deep vein thrombosis, normochromatic and normocytic anaemia, glossitis, diarrhoea and psychological manifestations [15] .
Somatostatinomas
Somatostatinomas are classified as tumors that are predominantly or exclusively composed of somatostatinproducing cells. They are more frequently found in women and are situated in the duodenum or pancreas (in 57% and 43% of cases, respectively). Duodenal somatostatinomas may be found incidentally in the course of an endoscopic examination. When localised in Vater's ampolla, they can determine symptoms and signs of obstruction and bilious-pancreatic reflux. Otherwise, they may occasionally manifests with a digestive haemorrhage due to ulceration of the tumour. Duodenal somatostatinomas are frequently associated with Von Recklinghausen's disease, and only rarely with MEN1.
Somatostatinomas, whether of the duodenal or pancreatic variety, are always associated with a syndrome characterised by gall-bladder stones, diabetes mellitus and diarrhoea with steatorrhoea [16] .
GRFomas
GRFomas -the extremely rare endocrine tumors that secrete growth-releasing factor (GRF) -lead to acromegaly. They always under the age of 40 years, and are more often found in females (with a male/female ratio of 1/3). They are commonly located, in the head of the pancreas, and run a malignant course in 30% of cases. GRFomas are frequently associated with other endocrine disorders, especially in the MEN1 group, such as hyperparathyroidism, Zollinger-Ellison syndrome, hypoglycaemia, Cushing's syndrome and pheochromocytoma, which is frequently multiple [17] .
Non-functioning pancreatic tumours
This group of tumours are said to be 'non-functioning' in as much as they are not associated with clinical symptoms caused by hormonal hypersecretion. They are almost exclusively situated in the pancreas, nonfunctioning pancreatic tumours account for about 20% of all the endocrine tumours of this organ. Histologically, they are constituted of insulin (50%), pancreatic polypeptide (40%), glucagon (30%) and somatostatin (13%) cells. Except when associated with MEN1, nonfunctioning pancreatic tumours are generally unifocal. They are most often diagnosed in the 4th to 5th decade of life. Their symptomatology varies with size. In the initial phase, they are generally asymptomatic and, are thus discovered only by chance when diagnostic imaging procedures are performed for other reasons. In the more advanced stages, or in the presence of metastasis, symptoms such as epigastric pain, vague abdominal pain, weight loss and jaundice appear, as a result of the tumour mass. Their early clinical silence could be due to a combination of factors, including low -or inactivepeptide production, co-secretion of peptide inhibitors and, last but not least, the down-regulation of peripheral receptors [18] .
Diagnosis of GEP endocrine tumours
Biochemical diagnosis
The initial diagnosis of GEP endocrine tumours is often biochemical. In any case, the specific biochemical diagnosis is always fundamental for the clinical workup of GEP endocrine tumour patients. As well as in the presence of any of the main syndromes, the possibility of a GEP endocrine tumour should also be considered in patients who present widespread abdominal symptoms. Nowadays, the main screening marker is chromogranin A (CgA), a glycoprotein present in almost all neuroendocrine cells. Raised plasma CgA levels are found in the vast majority of patients with GEP endocrine tumour (as well as in the presence of pheochromocytomas, ganglioneuromas and neuroblastomas). Other general markers of GEP endocrine tumours are pancreatic polypeptide, human chorionic gonadotropin (HCG) a and HCG-p. As regards markers specific for functioning tumours, urinary 5-HIAA pecific markers for carcinoids, and especially for midgut ones. Serum gastrin, plasma somatostatin and ACTH are specific for foregut carcinoids. Specific markers that can be seleced on the basis of symptomatology for diagnosis of the various types of endocrine tumours of the pancreas include, gastrin, insulin, pancreatic polypeptide, somatostatin, VIP and glucagon [19] .
Localisation procedures
The basic imaging workup is currently based on computerised tomography (CT) scan, magnetic resonance imaging (MRI), ultrasound, somatostatin receptor scintigraphy (SRS) and positron emission tomography. Various forms of endoscopy are important for tumour localisation. Endoscopic ultrasound is capable of detecting some small endocrine pancreatic tumours. Today SRS is the most important imaging tool used in screening for GEP endocrine tumours. It is also used alongside ultrasonography, CT-scan and/or MRI for monitoring therapy. Of course it should be supplemented by a, necessary to follow during therapy [20] .
